BMO
LGND icon

Beck Mack & Oliver’s Ligand Pharmaceuticals LGND Stock Holding History

Beck Mack & Oliver’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$415K Sell
1,314
-380
-22% -$89.5K 0.01% 146
2026
Q1 		$338K Buy
+1,694
New +$335K 0.01% 155

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Beck Mack & Oliver's LGND Position: Q2 2026 in Review

Beck Mack & Oliver reduced its Ligand Pharmaceuticals (LGND) stake by 22% in Q2 2026, selling an estimated $89.5K and leaving 1,314 shares worth $415K. The position accounts for 0.01% of the portfolio, ranked #146.

Beck Mack & Oliver first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Beck Mack & Oliver held 1,314 shares of Ligand Pharmaceuticals worth $415K as of Q2 2026.
  • Beck Mack & Oliver sold 380 Ligand Pharmaceuticals shares in Q2 2026, an estimated $89.5K.
  • Ligand Pharmaceuticals made up 0.01% of Beck Mack & Oliver's portfolio in Q2 2026, its #146 holding.
  • Beck Mack & Oliver first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Beck Mack & Oliver's 13F filing for Q2 2026, filed 14 Aug 2026.